[{"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127-001", "question": "A 56-year-old man with long-standing type 2 diabetes, CKD stage 3b, and prior NSTEMI presents for routine follow-up. Medications: metformin 500 mg BID, empagliflozin 10 mg daily, lisinopril 20 mg daily, metoprolol succinate 100 mg daily, and high-intensity statin. BP is 118/66 mm Hg, BMI 31 kg/m², A1c 7.2%. eGFR is 37 mL/min/1.73 m², urinary ACR 620 mg/g (persistent over 9 months), potassium 4.6 mEq/L. He has no hyperkalemia history. Which change in therapy is most appropriate to further reduce his cardiorenal risk?", "options": ["Increase empagliflozin to 25 mg daily", "Add finerenone with close potassium monitoring", "Replace lisinopril with sacubitril/valsartan", "Add basal insulin to target A1c <6.5%", "Add a non-dihydropyridine calcium channel blocker"], "answer": "B", "answer_index": 1, "explanation": "Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, reduces CV events and CKD progression in diabetics with albuminuric CKD already on ACEi/ARB and SGLT2i and with eGFR >25 and K<4.8. Increasing SGLT2 dose adds minimal incremental renal protection, sacubitril/valsartan is not indicated without HFrEF, tighter glycemic control adds little cardiorenal benefit with more risk, and non-DHP CCBs do not provide proven outcome benefit here.", "generator_model": "gpt-5.1-2025-11-13", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "Based on current clinical guidelines (ADA Standards of Care, KDIGO Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease), patients with type 2 diabetes and chronic kidney disease who have persistent albuminuria despite standard-of-care treatment (which includes a maximally tolerated ACE inhibitor or ARB and an SGLT2 inhibitor) are at high residual risk for CKD progression and cardiovascular events.\n\nThe pivotal complications trials FIDELIO-DKD and FIGARO-DKD demonstrated that finerenone, a non-steroidal mineralocorticoid receptor antagonist (MRA), significantly reduced the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular events (including cardiovascular death, non-fatal MI, non-fatal stroke, or hospitalization for heart failure) in this patient population.\n\nThe patient is currently on lisinopril (ACE inhibitor) and empagliflozin (SGLT2 inhibitor) with controlled blood pressure but persistent severe albuminuria (620 mg/g). His potassium is 4.6 mEq/L (cutoff for initiation is typically $\\le$ 5.0 mEq/L). Therefore, the addition of finerenone is the most appropriate next step to further reduce his cardiorenal risk.\n\nIncreasing empagliflozin (Option A) offers minimal additional cardiorenal benefit over the 10 mg dose. Sacubitril/valsartan (Option C) is indicated for heart failure, which is not stated as a diagnosis here, and evidence for primary CKD progression is weaker than for MRAs. Intensive glycemic control (Option D) increases hypoglycemia risk without lowering cardiorenal events significantly. Non-dihydropyridine CCBs (Option E) are contraindicated with beta-blockers due to bradycardia risk and are less effective for hard cardiorenal outcomes than MRAs.\n\nThe answer is (B)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127-002", "question": "A 4-year-old boy is brought to the ED with 2 days of fever, abdominal pain, and vomiting. PMH includes Kawasaki disease at 11 months treated with IVIG and aspirin; echocardiography then showed a 7-mm giant aneurysm of the left anterior descending coronary artery, which has since regressed to normal dimensions by age 3. He is off antiplatelets and asymptomatic at baseline. Current vitals: T 39.2°C, HR 145/min, BP 82/48 mm Hg, RR 30/min, SpO2 95% RA. He appears ill and mottled with cool extremities. ECG shows sinus tachycardia with ST-segment depression in V4-V6. High-sensitivity troponin is mildly elevated. Bedside echo shows mild global LV dysfunction (EF 45%), no visible aneurysm. After fluid resuscitation and initiation of broad-spectrum antibiotics, which management step is most appropriate now?", "options": ["Re-treat with high-dose IVIG and start high-dose aspirin", "Obtain emergent coronary CT angiography and start IV heparin", "Start IV milrinone and low-dose aspirin without additional imaging", "Start IV methylprednisolone plus IVIG and transfer for ECMO standby", "Begin norepinephrine for septic shock and defer cardiac-specific therapy"], "answer": "B", "answer_index": 1, "explanation": "Children with prior giant Kawasaki aneurysms remain at risk for thrombosis and stenosis despite angiographic regression; acute coronary syndrome can mimic sepsis. ST depression, hypotension, and troponin elevation warrant urgent coronary imaging (CT angiography) and antithrombotic therapy. Routine retreatment with IVIG is not indicated years later, steroids/ECMO are premature without refractory shock, and treating as isolated sepsis risks missing coronary occlusion.", "generator_model": "gpt-5.1-2025-11-13", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "This patient presents with signs of cardiogenic shock (tachycardia, hypotension, cool extremities, mottled skin, depressed EF) and specific evidence of myocardial ischemia (ST-segment depression in V4-V6, elevated troponin) in the context of a history of a giant Kawasaki disease (KD) aneurysm of the Left Anterior Descending (LAD) artery.\n\n1.  Understand the Pathology: Although the giant aneurysm (7-mm) \"regressed\" to normal dimensions by echocardiography, the vessel wall healing process typically involves intimal thickening, fibrosis, and calcification. This often results in a vessel that has a normal or narrow lumen (hence no aneurysm seen on current echo) but is functionally stiff and prone to high-grade stenosis or acute thrombosis. Echocardiography is notoriously poor at visualizing coronary stenosis or thrombosis in these \"healed\" vessels.\n\n2.   Recognize the Clinical Syndrome: In children, acute myocardial infarction (AMI) often presents with nonspecific symptoms such as abdominal pain, vomiting, and restlessness/shock, rather than classic chest pain. The fever and tachycardia likely increased myocardial oxygen demand, precipitating ischemia in a stenotic vessel or triggering a plaque rupture/thrombosis. The ECG findings (ST depression in V4-V6) correlate perfectly with the previous LAD pathology.\n\n3.  Evaluate Management Options:\n    *   A: Retreating for acute or recurrent/incomplete KD (IVIG/Aspirin) does not address the immediate life-threatening coronary occlusion/ischemia. High-dose aspirin is not sufficient anticoagulation for an acute thrombus.\n    *   B: The clinical picture is Acute Coronary Syndrome/AMI. The AHA guidelines for the management of myocardial infarction in children with a history of KD recommend immediate consultative care, stabilization, and antithrombotic therapy (heparin). Visualization of the coronary anatomy is critical to determine the need for interventional reperfusion (PCI) or surgery (CABG). Since echocardiography has limited utility for stenosis/thrombosis, Emergent coronary CT angiography (CCTA) (or invasive angiography) is necessary to define the anatomy. IV Heparin is the standard immediate treatment to prevent thrombus propagation and stabilize the plaque.\n    *   C: Milrinone might improve contractility, but without addressing the coronary obstruction, the ischemia will worsen. Furthermore, milrinone is a vasodilator and could dangerously lower the blood pressure further in this hypotensive child.\n    *   D: This management targets MIS-C (Multisystem Inflammatory Syndrome in Children). While MIS-C is a differential, the localized ECG changes matching the specific history of LAD aneurysm strongly favor a structural coronary event over the global inflammation/myocarditis of MIS-C.\n    *   E: Norepinephrine fits septic shock management, but \"deferring cardiac-specific therapy\" in a patient with active ST-segment changes and troponin elevation is incorrect and potentially fatal.\n\nConclusion: The patient is suffering from an acute myocardial infarction secondary to KD sequelae (stenosis/thrombosis). Immediate anticoagulation and coronary imaging are required.\n\nThe answer is (B)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127-003", "question": "A 32-year-old woman presents with 3 weeks of migratory polyarthritis, pleuritic chest pain, and low-grade fever. Exam: malar rash sparing nasolabial folds, small bilateral pleural effusions, and mild synovitis of wrists and MCPs. Labs: Hb 10.4 g/dL, platelets 145,000/µL, WBC 3,200/µL, Cr 0.8 mg/dL, urine protein/Cr ratio 0.2, AST/ALT mildly elevated. ESR 75 mm/h, CRP 2.1 mg/dL. ANA 1:640 homogeneous, anti-dsDNA high, low C3/C4. Anti-phospholipid antibodies are negative on two occasions 12 weeks apart. Echocardiogram shows a small pericardial effusion without tamponade. She has a confirmed positive pregnancy test at 6 weeks gestation. Which of the following is the most appropriate initial treatment strategy?", "options": ["Start high-dose prednisone plus mycophenolate mofetil", "Start hydroxychloroquine and low-moderate dose prednisone", "Start methotrexate and high-dose NSAIDs", "Defer immunosuppression and treat with low-dose aspirin alone", "Start belimumab and discontinue hydroxychloroquine once controlled"], "answer": "B", "answer_index": 1, "explanation": "This is new-onset SLE with non-organ-threatening disease in early pregnancy; hydroxychloroquine is recommended in all pregnant SLE patients and improves maternal and fetal outcomes. Low-moderate dose prednisone addresses serositis and arthritis with acceptable fetal safety. Mycophenolate and methotrexate are teratogenic, aspirin alone is inadequate for active disease, and belimumab is not first-line in new, non-severe SLE in pregnancy.", "generator_model": "gpt-5.1-2025-11-13", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "This patient has a new diagnosis of Systemic Lupus Erythematosus (SLE) characterized by malar rash, arthritis, serositis (pleuritis, pericardial effusion), hematologic abnormalities, and positive serology. Crucially, she is 6 weeks pregnant. The management of SLE during pregnancy requires controlling disease activity to ensure the best outcomes for both mother and fetus while avoiding teratogenic medications.\n\n1.  Hydroxychloroquine (HCQ) is the standard of care for all SLE patients, including pregnant women. It reduces disease activity, prevents flares, and is associated with favorable pregnancy outcomes. It is considered safe during pregnancy.\n2.  Corticosteroids (Prednisone) are generally safe in pregnancy (though the lowest effective dose is preferred to minimize risks like gestational diabetes and hypertension). They are safer than NSAIDs in the first trimester and are effective for managing acute symptoms like serositis and arthritis while HCQ reaches therapeutic levels.\n3.  Mycophenolate mofetil (Option A) and Methotrexate (Option C) are teratogenic and contraindicated during pregnancy. Mycophenolate is associated with embryopathy and pregnancy loss. Methotrexate is a folate antagonist causing fetal malformations.\n4.  Deferring immunosuppression (Option D) is inappropriate because the patient has active disease (fever, serositis, arthritis, high inflammatory markers). Active SLE is a significant risk factor for adverse pregnancy outcomes (e.g., preterm birth, preeclampsia, fetal loss).\n5.  Belimumab (Option E) is a monoclonal antibody. While data is accumulating, it is not the standard first-line initiation therapy over HCQ, particularly in pregnancy. Furthermore, HCQ should not be discontinued as it provides long-term protective benefits.\n\nTherefore, the combination of hydroxychloroquine and low-to-moderate dose prednisone is the most appropriate initial strategy to control active symptoms safely.\n\nThe answer is (B)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127-004", "question": "A 61-year-old man with obesity and hypertension presents with exertional dyspnea and occasional chest tightness. Resting ECG is normal. Transthoracic echocardiogram shows EF 60%, mild concentric LVH, and no valvular disease. He undergoes a standard exercise treadmill test using Bruce protocol. At stage 3, he develops 2-mm horizontal ST depression in leads V4-V6 and II, III, aVF with peak HR 142/min (89% of predicted). He has no chest pain and BP rises appropriately. Nuclear perfusion imaging done concurrently shows normal perfusion and normal LV function at rest and stress. Coronary CT angiography reveals a short left main with separate LAD and LCx ostia, no atherosclerotic plaque, and a myocardial bridge in the mid-LAD with 80% systolic compression but preserved diastolic lumen. Which is the best next step in management?", "options": ["Start high-dose beta-blocker therapy and avoid further ischemic workup", "Refer for percutaneous coronary intervention with stenting of the bridged segment", "Order invasive coronary angiography with pressure-wire assessment during dobutamine stress", "Schedule surgical myotomy of the myocardial bridge", "Reassure the patient and no further follow-up is required"], "answer": "C", "answer_index": 2, "explanation": "The discordance between ischemic ST changes and normal perfusion imaging in the setting of a significant myocardial bridge raises concern for dynamic flow limitation, especially at higher heart rates not reached on standard testing. Invasive angiography with physiologic assessment (FFR/iFR or diastolic FFR during inotropic stress) clarifies hemodynamic significance and guides need for intensified medical or surgical therapy. Empiric high-dose beta-blockers or surgery without confirming significance is premature, and PCI in bridged segments has high complication rates.", "generator_model": "gpt-5.1-2025-11-13", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "This patient presents with symptoms of stable angina (exertional dyspnea and chest tightness) and has a positive exercise stress test (ST depression) but a normal nuclear perfusion scan. Coronary CT angiography (CCTA) rules out atherosclerotic coronary artery disease (CAD) but identifies a myocardial bridge in the mid-LAD with significant systolic compression.\n\nAnalysis of the Clinical Scenario:\n1.  Diagnosis: The combination of exertional symptoms, ischemic ECG changes during stress, absence of atherosclerotic plaque, and the presence of a myocardial bridge strongly suggests that the myocardial bridge is the cause of the symptoms. While systolic compression is the hallmark of bridging, ischemia can occur due to tachycardia shortening diastole (when coronary flow occurs) and delayed relaxation of the artery into early diastole.\n2.  Discordant Testing: It is common for myocardial bridges to show conflicting results between functional tests. ST depression on exercise ECG is frequent, while perfusion imaging (SPECT) may be normal (false negative) due to the nature of the ischemia or limitations in the resolution of the test for this specific pathophysiology. The normal perfusion scan should not preclude treatment in a symptomatic patient with demonstrated anatomy and electrical ischemia.\n3.  Management:\n    *   First-line therapy: Beta-blockers are the mainstay of treatment for symptomatic myocardial bridges. They act by decreasing heart rate (increasing diastolic clinical filling time and reducing the frequency of compression) and decreasing contractility (reducing the force of systolic compression).\n    *   Invasive testing: Invasive angiography with dobutamine stress and diastolic pressure wire assessment (e.g., dFFR or iFR) is the gold standard for assessing hemodynamic significance. However, this is invasive and typically reserved for patients who remain symptomatic despite optimal medical therapy or when considering surgical revascularization.\n    *   Intervention: Surgical myotomy is reserved for refractory cases. Stenting is generally contraindicated due to high rates of stent fracture and restenosis from the external compressive forces.\n\nEvaluation of Options:\n*   A. Start high-dose beta-blocker therapy and avoid further ischemic workup: This is the most appropriate next step. The patient is symptomatic and has a diagnosis consistent with the findings. A trial of medical therapy is indicated before subjecting the patient to invasive risks. The presence of hypertension also supports the use of beta-blockers. The instruction to \"avoid further ischemic workup\" implies that the diagnosis is sufficiently established by the CCTA and clinical presentation to warrant treatment.\n*   B. Refer for PCI: Stenting is associated with poor outcomes in bridging (fracture, perforation) and is rarely performed.\n*   C. Order invasive coronary angiography with dobutamine: While this is a diagnostic tool for bridges, it is not the *first* step in management. It is indicated if the patient fails medical therapy.\n*   D. Surgical myotomy: This is a major surgery reserved for medication-refractory patients.\n*   E. Reassure: The patient is symptomatic with objective ST segment deviations. Ignoring these findings is not appropriate management.\n\nTherefore, initiating medical therapy with beta-blockers is the standard of care.\n\nThe answer is (A)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127-005", "question": "A 28-year-old woman at 36 weeks gestation presents to the ED with severe headache, visual blurring, and nausea. BP is 188/118 mm Hg, HR 96/min. She is agitated and reports seeing flashing lights. Reflexes are brisk with 3+ patellar reflexes and 1-2 beats of clonus. Labs: platelets 102,000/µL, AST 105 U/L, ALT 98 U/L, Cr 1.2 mg/dL, urine protein/Cr ratio 1.0. Shortly after arrival, she has a generalized tonic-clonic seizure lasting 90 seconds, then becomes postictal. Oxygen saturation is 95% on 2 L nasal cannula. Fetal heart monitoring is reassuring. She has already received a 4-g IV loading dose of magnesium sulfate en route. Which is the most appropriate immediate next step after stabilizing airway and breathing?", "options": ["Administer an additional 2-g IV magnesium bolus and start IV labetalol", "Start continuous propofol infusion and emergent head CT before antihypertensives", "Give IV levetiracetam, discontinue magnesium, and proceed to emergent cesarean delivery", "Start nicardipine infusion targeting BP <120/80 mm Hg and delay delivery for 48 hours", "Administer IV diazepam and begin oral labetalol once she awakens"], "answer": "A", "answer_index": 0, "explanation": "She has eclampsia with severe features; magnesium is first-line for seizure control and recurrence prevention, and a repeat bolus is appropriate after a breakthrough seizure on therapy. Rapid parenteral antihypertensive (e.g., IV labetalol) is needed to control severe BP, with expeditious delivery once stabilized. Propofol, levetiracetam alone, aggressive BP lowering to normal, or delaying delivery are not appropriate initial strategies.", "generator_model": "gpt-5.1-2025-11-13", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "This patient presents with eclampsia, defined by the occurrence of generalized tonic-clonic seizures in a patient with preeclampsia. The management of eclampsia involves stabilization of the mother (ABCs), control of seizures, and management of severe hypertension, followed by delivery.\n\n1.  Seizure Management: Magnesium sulfate is the first-line agent for the prevention and treatment of eclamptic seizures, as it is superior to benzodiazepines and phenytoin. This patient received a 4-g loading dose en route but subsequently had a seizure. In the setting of a recurrent seizure (or a seizure occurring after a loading dose has been given), guidelines (such as those from ACOG) recommend administering an additional 2-g IV bolus of magnesium sulfate. The patient's reflexes are brisk (3+), indicating she is not suffering from magnesium toxicity (which would manifest as loss of deep tendon reflexes), so an additional dose is safe.\n\n2.  Blood Pressure Management: The patient has severe hypertension (188/118 mm Hg). Acute-onset severe hypertension in pregnancy/postpartum is a hypertensive emergency that requires immediate treatment to prevent stroke. First-line agents include IV labetalol or IV hydralazine (or oral nifedipine if IV access is not available).\n\n3.  Delivery Planning: While delivery is the definitive treatment, the patient must be hemodynamically stabilized first (seizures controlled, BP lowered, hypoxia corrected). Rushing to cesarean section (Option C) while the patient is unstable increases maternal risk. Conversely, delaying delivery for 48 hours (Option D) is contraindicated in eclampsia; delivery should occur once the patient is stable.\n\nTherefore, the most appropriate immediate next step is to treat the breakthrough seizure activity with additional magnesium and treat the hypertensive emergency.\n\nThe answer is (A)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127-006", "question": "A 9-year-old boy presents with 3 months of diffuse musculoskeletal pain, morning stiffness lasting 30-45 minutes, and profound fatigue. He was previously athletic but now avoids activity due to pain. Exam shows generalized tenderness over muscles and entheses, mild limitation of lumbar flexion, and no clear joint effusions. No rash, fevers, or weight loss. Labs: CBC, ESR, CRP, CK, aldolase, and TSH are normal. ANA 1:80 speckled, RF negative, HLA-B27 negative. XR of sacroiliac joints and spine are normal. He has fragmented sleep, difficulty focusing at school, and abdominal pain without alarm features. Which strategy is most appropriate to establish the correct diagnosis and direct management?", "options": ["Order whole-body MRI to evaluate for enthesitis-related arthritis or occult malignancy", "Diagnose juvenile fibromyalgia and implement a graded exercise and CBT program", "Perform lumbar puncture and brain MRI to evaluate for CNS vasculitis", "Start a 3-month trial of NSAIDs and low-dose prednisone for suspected JIA", "Order EMG and nerve conduction studies to exclude small fiber neuropathy"], "answer": "B", "answer_index": 1, "explanation": "Chronic widespread pain, normal inflammatory and muscle markers, non-restorative sleep, cognitive complaints, and functional GI symptoms are characteristic of juvenile fibromyalgia. Early diagnosis with emphasis on graded aerobic/strength exercise and cognitive behavioral therapy is key. Whole-body MRI, CNS workup, empiric steroids, or EMG are unnecessary and potentially harmful in this presentation.", "generator_model": "gpt-5.1-2025-11-13", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "This patient presents with a classic clinical picture of Juvenile Primary Fibromyalgia Syndrome (JPFS), also referred to as a juvenile amplified musculoskeletal pain syndrome (AMPS).\n\n1.  Clinical Features: The hallmark features are chronic (>3 months) diffuse musculoskeletal pain, generalized tenderness (allodynia/hyperalgesia) on exam, and profound fatigue. Associated somatic symptoms are highly characteristic and include non-restorative sleep (\"fragmented sleep\"), cognitive dysfunction (\"difficulty focusing\"), and functional abdominal pain.\n2.  Physical Exam: The exam demonstrates generalized tenderness over muscles and entheses without objective signs of inflammation (no joint effusions, warmth, or erythema). The mild limitation of lumbar flexion is likely due to pain guarding or deconditioning rather than inflammatory spinal fusion (especially given the short duration and normal X-rays).\n3.  Laboratory/Imaging Findings: The most important finding is the absence of inflammation. CBC, ESR, CRP, and muscle enzymes (CK, aldolase) are normal. This effectively argues against Juvenile Idiopathic Arthritis (JIA), dermatomyositis, or systemic vasculitis. The ANA is low-titer (1:80) and non-specific, seen frequently in the healthy population and children with chronic pain. HLA-B27 is negative, and sacroiliac X-rays are normal, making ankylosing spondylitis/enthesitis-related arthritis unlikely.\n\nEvaluation of Options:\n*   Option B: This is the correct strategy. Juvenile fibromyalgia is a clinical diagnosis based on the presence of widespread pain and somatic symptoms in the absence of inflammatory markers or other pathology. The gold standard management involves a multidisciplinary approach focusing on graded aerobic exercise (to retrain pain pathways and improve conditioning) and Cognitive Behavioral Therapy (CBT) (to address coping mechanisms, sleep hygiene, and the fear-avoidance cycle).\n*   Option A: Whole-body MRI is expensive and unnecessary given the normal inflammatory markers and classic \"central sensitization\" phenotype. Malignancy is unlikely without \"red flags\" like fever, weight loss, night pain, or cytopenias.\n*   Option C: There are no focal neurological deficits or inflammatory markers to suggest CNS vasculitis.\n*   Option D: A trial of steroids is inappropriate without a confirmed diagnosis of inflammation, as it exposes the child to toxicity without benefit for nociplastic pain conditions like fibromyalgia.\n*   Option E: Small fiber neuropathy is a rare cause of diffuse pain in children and typically presents with distal burning/sensory changes rather than diffuse muscle/enthesis tenderness. Standard EMG tests large fibers, not small fibers.\n\nThe answer is (B)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127-007", "question": "A 63-year-old woman with a 15-year history of seropositive rheumatoid arthritis (RA) presents with progressive dyspnea and dry cough over 4 months. Medications: methotrexate 20 mg weekly (for 10 years), low-dose prednisone 5 mg daily, and adalimumab for 3 years. She has no fevers or weight loss. Exam reveals bibasilar fine inspiratory crackles and mild digital clubbing. PFTs show FVC 62% predicted, FEV1/FVC 0.85, and DLCO 40% predicted. HRCT of the chest shows subpleural reticulation, traction bronchiectasis, and honeycombing predominantly in the bases, consistent with a usual interstitial pneumonia (UIP) pattern. There are no ground-glass opacities. Which is the most appropriate modification of her RA and lung disease management?", "options": ["Discontinue methotrexate permanently and increase adalimumab dose", "Continue current RA regimen and add nintedanib", "Stop adalimumab and switch to rituximab while continuing methotrexate", "Stop methotrexate and adalimumab, and start high-dose prednisone plus azathioprine", "Add mycophenolate mofetil to current regimen for treatment of ILD"], "answer": "B", "answer_index": 1, "explanation": "This is RA-associated ILD with a UIP pattern, which behaves like idiopathic pulmonary fibrosis and typically does not respond to high-dose immunosuppression. Nintedanib slows FVC decline in progressive fibrosing ILDs, including RA-ILD, and can be added while stable articular disease is controlled. Routine methotrexate cessation is not clearly beneficial here, and switching biologics or adding mycophenolate is more appropriate for inflammatory (e.g., NSIP) patterns rather than established fibrotic UIP.", "generator_model": "gpt-5.1-2025-11-13", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "This patient has rheumatoid arthritis-associated interstitial lung disease (RA-ILD) with a usual interstitial pneumonia (UIP) pattern on HRCT. The management requires addressing both the systemic RA control and the specific lung pathology.\n\n1.  Methotrexate (MTX) considerations: Historically, MTX was associated with hypersensitivity pneumonitis, which typically presents acutely with ground-glass opacities. Recent evidence and guidelines (e.g., 2023 ACR guidelines) indicate that MTX is not associated with an increased risk of developing chronic fibrotic ILD (like UIP) and may be continued in patients with RA-ILD to control joint disease, provided there is no evidence of acute hypersensitivity pneumonitis. Therefore, stopping MTX is generally not required for this patient's presentation.\n\n2.  TNF Inhibitors (Adalimumab): The use of TNF inhibitors in RA-ILD is controversial, with several studies and guidelines suggesting an association with ILD progression or exacerbation. Current ACR guidelines conditionally recommend withdrawing TNF inhibitors in patients with RA-ILD and switching to alternative biologics that have a better safety profile or potential efficacy for the lungs.\n\n3.  Rituximab: B-cell depletion with rituximab has demonstrated efficacy in stabilizing or improving lung function in patients with RA-ILD, including those with a UIP pattern. It is considered a preferred biologic agent for this condition.\n\n4.  Other Options:\n    *   Nintedanib (Option B): While nintedanib is approved for chronic fibrosing ILDs with a progressive phenotype, the primary management step in RA-ILD is optimizing the immunomodulatory regimen. This involves removing potentially harmful agents (TNFi) and initiating agents with lung efficacy (rituximab). Nintedanib is typically added if progression occurs despite optimal immunosuppression.\n    *   Prednisone/Azathioprine (Option D): Combination therapy with high-dose prednisone and azathioprine is discouraged for UIP patterns (based on extrapolation from IPF data showing harm) and is not the first-line switch for RA-ILD.\n    *   Mycophenolate (Option E): While used in CTD-ILD, adding it without addressing the TNF inhibitor is less optimal than switching the biologic to rituximab.\n\nTherefore, the most appropriate modification is to discontinue the TNF inhibitor (adalimumab), which may worsen ILD, and switch to rituximab, which treats both the joints and the lung disease, while continuing the effective background therapy with methotrexate.\n\nThe answer is (C)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127-008", "question": "A 45-year-old man with poorly controlled type 2 diabetes (A1c 10.8%), BMI 36 kg/m², and mild nonproliferative diabetic retinopathy presents for follow-up. Medications: metformin 1000 mg BID and basal insulin glargine 35 units nightly. He had an episode of acute pancreatitis 3 years ago attributed to severe hypertriglyceridemia (TG 1,800 mg/dL); since then, triglycerides have been controlled around 250-300 mg/dL on fenofibrate. He drinks no alcohol. eGFR is 65 mL/min/1.73 m², AST/ALT are mildly elevated (1.5× ULN), and ultrasound shows fatty liver without biliary disease. He is interested in newer injectable therapies for weight loss and glucose control. Which glucose-lowering agent is most appropriate to add now?", "options": ["Liraglutide", "Semaglutide", "Dulaglutide", "Tirzepatide", "Empagliflozin"], "answer": "E", "answer_index": 4, "explanation": "Given prior pancreatitis, any incretin-based therapy (GLP-1 receptor agonists and dual GIP/GLP-1 agonists like tirzepatide) carries a theoretical risk of recurrence, and product labels recommend caution or avoidance. An SGLT2 inhibitor such as empagliflozin improves glycemic control, promotes modest weight loss, and provides CV/renal benefits without known pancreatitis signal. His eGFR is adequate, making empagliflozin the safest choice among the listed options.", "generator_model": "gpt-5.1-2025-11-13", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "E", "model_outputs": "This patient has poorly controlled type 2 diabetes, obesity, and established fatty liver disease. He is seeking better control and weight loss. The most critical factor in his history influencing the choice of a new agent is the history of acute pancreatitis.\n\n1.  Contraindications/Precautions (History of Pancreatitis):\n    *   Liraglutide (A), Semaglutide (B), Dulaglutide (C), and Tirzepatide (D): These are all incretin-based therapies (GLP-1 receptor agonists or dual GIP/GLP-1 receptor agonists). The prescribing information for all these agents contains a warning regarding the risk of acute pancreatitis. Specifically, the labels state that these drugs have not been studied in patients with a history of pancreatitis and that other antidiabetic therapies should be considered in such patients. While the patient's previous pancreatitis was attributed to hypertriglyceridemia, the safety of initiating incretin-based therapies in patients with a prior history of pancreatitis is not established and is generally avoided in board examination contexts when a safe alternative exists.\n    *   Additionally, regarding Semaglutide (B): The SUSTAIN-6 trial showed an increased risk of diabetic retinopathy complications in patients with a history of retinopathy and high A1c who experienced rapid glucose lowering. This patient has both mild nonproliferative retinopathy and a high A1c, adding another layer of caution for semaglutide specifically.\n\n2.  Appropriateness of Empagliflozin (E):\n    *   Empagliflozin is an SGLT2 inhibitor. It does not carry a risk for pancreatitis, making it safe to use in this patient with a prior history of the condition.\n    *   It promotes weight loss (though generally less than GLP-1 RAs/Tirzepatide) and improves glycemic control.\n    *   It has established benefits for delaying the progression of kidney disease and reducing heart failure hospitalization.\n    *   Recent guidelines also support the use of SGLT2 inhibitors in patients with metabolic dysfunction-associated steatotic liver disease (MASLD/fatty liver), as they can reduce liver fat content and liver enzymes.\n    *   His eGFR (65 mL/min/1.73 m²) allows for the safe initiation of an SGLT2 inhibitor.\n\nGiven the history of pancreatitis, the incretin-based therapies (Options A, B, C, D) are relatively contraindicated or not the preferred first-line additions compared to an agent with a neutral pancreatic safety profile like an SGLT2 inhibitor.\n\nThe answer is (E)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127-009", "question": "A 27-year-old woman is brought to the ED after collapsing during a 10-km race. Bystanders report sudden loss of consciousness without seizure activity; CPR was started immediately, and an AED delivered one shock for ventricular fibrillation with ROSC. She is now awake and oriented. No drugs or supplements; family history notable for an uncle who died suddenly at 32 while swimming, presumed drowning. Vitals: HR 78/min, BP 112/68 mm Hg, normal exam. Labs and echocardiogram are normal. Baseline ECG shows QTc 460 ms, normal QRS, and normal ST-T waves. During recovery from an exercise treadmill test, she develops polymorphic VT that terminates spontaneously; QTc in recovery is 510 ms with late-appearing T waves in V2-V4. Which is the most appropriate next step in management?", "options": ["Implant an ICD and start high-dose beta-blocker therapy", "Start nadolol and schedule left cardiac sympathetic denervation", "Start flecainide in addition to beta-blocker therapy", "Begin verapamil and restrict participation to low-intensity sports", "Perform genetic testing for catecholaminergic polymorphic VT before any therapy"], "answer": "A", "answer_index": 0, "explanation": "This presentation is consistent with congenital long QT syndrome (likely LQT1 or LQT2) with exercise-associated VF arrest and marked QT prolongation in recovery. Survivors of cardiac arrest from LQTS require ICD plus beta-blocker therapy. LCSD or flecainide may be adjuncts in selected cases but not first-line over ICD after arrest. Verapamil is ineffective, and genetic testing should not delay life-saving therapy.", "generator_model": "gpt-5.1-2025-11-13", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "The patient's clinical presentation is highly suggestive of Long QT Syndrome Type 1 (LQT1). The key features include:\n1.  Exertional Cardiac Arrest: The event occurred during a race (high adrenergic state). LQT1 is classically triggered by exercise.\n2.  Family History: The uncle dying suddenly while swimming is a pathognomonic historical clue for LQT1.\n3.  Stress Test Response: The QT interval prolonged during the recovery phase of exercise (paradoxical prolongation). In normal physiology, the QT interval should shorten appropriately with tachycardia. In LQT1, the defect in the slow delayed rectifier potassium current ($I_{Ks}$) impairs QT shortening during tachycardia and recovery, leading to the arrhythmogenic substrate.\n\nWhile the description of \"late-appearing T waves\" can sometimes refer to LQT3 morphologically, the exertional nature of the arrest and the swimming death in the family strongly rule out LQT3 (which typically presents with events during sleep/rest) and LQT2 (auditory/emotional triggers). CPVT is ruled out by the baseline QT prolongation and the paradoxical QT lengthening during recovery (CPVT patients typically have normal resting and recovery QTc, with arrhythmia onset at peak stress).\n\nManagement:\nThis patient is a survivor of Sudden Cardiac Arrest (SCA). According to ACC/AHA/HRS guidelines:\n*   ICD implantation is a Class I recommendation for patients with LQTS who are survivors of SCA (secondary prevention).\n*   Beta-blockers are the mainstay of pharmacological therapy and are indicated for all symptomatic patients. High-dose therapy is often required for adequate protection.\n\nTherefore, the most appropriate next step is to ensure protection against recurrence with an ICD and to treat the underlying arrhythmia substrate with beta-blockers.\n\n*   Option B (Nadolol + LCSD) might be considered in specialized centers or if ICD is refused, but guidelines prioritize ICD for secondary prevention.\n*   Option C (Flecainide) is used for LQT3 or CPVT, not LQT1.\n*   Option D (Verapamil) is not a standard treatment for LQTS.\n*   Option E (Genetic testing first) causes an unacceptable delay in protecting a high-risk patient.\n\nThe answer is (A)"}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127-010", "question": "A 7-year-old boy with sickle cell disease (HbSS) presents with acute onset of severe left hip pain and inability to bear weight. He had a pain crisis 2 weeks ago treated with IV opioids and hydration. Temperature is 38.3°C, HR 120/min, BP 96/58 mm Hg. Hip exam reveals extreme pain with any passive motion, especially internal rotation, and the leg is slightly flexed and externally rotated. WBC 18,000/µL, CRP 14 mg/dL, ESR 86 mm/h. Plain radiograph is unremarkable. MRI of the pelvis obtained within 6 hours of symptom onset shows bone marrow edema of the femoral head and neck with a moderate hip joint effusion, but no definite abscess or cortical destruction. Which is the most appropriate next step?", "options": ["Treat as vaso-occlusive crisis with IV opioids and observe for 24-48 hours", "Start broad-spectrum IV antibiotics and schedule urgent surgical hip drainage", "Obtain radionuclide bone scan to differentiate infarction from osteomyelitis", "Repeat pelvic MRI with contrast in 72 hours before deciding on surgery", "Start IV antibiotics and aspirate the hip joint under ultrasound guidance"], "answer": "E", "answer_index": 4, "explanation": "In children with sickle cell disease, distinguishing osteomyelitis/septic arthritis from bone infarction is challenging; fever, high inflammatory markers, inability to bear weight, and effusion demand prompt evaluation. Joint aspiration with culture, ideally under ultrasound guidance, plus empiric IV antibiotics is the appropriate next step to diagnose or exclude septic arthritis early. Delaying for observation or repeat imaging risks joint destruction; bone scan is nonspecific in this setting, and immediate surgical drainage without diagnostic aspiration may be premature without frank clinical sepsis.", "generator_model": "gpt-5.1-2025-11-13", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "E", "model_outputs": "The clinical presentation of a 7-year-old boy with Sickle Cell Disease (HbSS), fever, severe hip pain, inability to bear weight, and elevated inflammatory markers (WBC, CRP, ESR) is highly suspicious for septic arthritis. However, in patients with sickle cell disease (SCD), a vaso-occlusive crisis (VOC) with bone infarction can mimic these findings, presenting with fever, pain, leukocytosis, and marrow edema on MRI. Additionally, VOC can cause a sterile sympathetic joint effusion.\n\nDistinguishing between septic arthritis and VOC/bone infarction is critical because the management differs significantly: septic arthritis requires urgent surgical drainage to prevent destruction of the femoral head, while VOC is managed medically. MRI alone often cannot definitively distinguish between the two in the acute setting (both show edema and effusion). As such, joint aspiration (arthrocentesis) is the required diagnostic step to analyze the synovial fluid (cell count, Gram stain, culture).\n\n*   Option A is incorrect because if the patient has septic arthritis, observation will lead to permanent joint destruction.\n*   Option B (Urgent surgical drainage) is the treatment for confirmed septic arthritis. However, given the high likelihood of VOC mimicking this presentation in an SCD patient, confirmation of purulence via aspiration is typically required before committing the patient to the risks of anesthesia and surgery.\n*   Option C (Bone scan) is useful for differentiating osteomyelitis from infarction in long bones, but for a joint presentation with an effusion, aspiration is the gold standard and provides immediate results.\n*   Option D involves an unacceptable delay.\n*   Option E is the best next step. It addresses the infection risk by starting antibiotics (usually after obtaining blood cultures/starting the procedure) and, most importantly, provides the definitive diagnosis via aspiration. If the aspirate is purulent, the patient proceeds to surgical washout; if sterile, unnecessary surgery is avoided.\n\nThe answer is (E)"}]